PortalPublikationenPrognostic relevance of gene amplifications and coamplificat...

Prognostic relevance of gene amplifications and coamplifications in breast cancer.

Standard

Prognostic relevance of gene amplifications and coamplifications in breast cancer. / Al-Kuraya, Khawla; Schraml, Peter; Torhorst, Joachim; Tapia, Coya; Zaharieva, Boriana; Novotny, Hedvika; Spichtin, Hanspeter; Maurer, Robert; Mirlacher, Martina; Köchli, Ossi; Zuber, Markus; Dieterich, Holger; Mross, Friedrich; Wilber, Kim; Simon, Ronald; Sauter, Guido.

in: CANCER RES, Jahrgang 64, Nr. 23, 23, 2004, S. 8534-8540.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Al-Kuraya, K, Schraml, P, Torhorst, J, Tapia, C, Zaharieva, B, Novotny, H, Spichtin, H, Maurer, R, Mirlacher, M, Köchli, O, Zuber, M, Dieterich, H, Mross, F, Wilber, K, Simon, R & Sauter, G 2004, 'Prognostic relevance of gene amplifications and coamplifications in breast cancer.', CANCER RES, Jg. 64, Nr. 23, 23, S. 8534-8540. <http://www.ncbi.nlm.nih.gov/pubmed/15574759?dopt=Citation>

APA

Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., Zuber, M., Dieterich, H., Mross, F., Wilber, K., Simon, R., & Sauter, G. (2004). Prognostic relevance of gene amplifications and coamplifications in breast cancer. CANCER RES, 64(23), 8534-8540. [23]. http://www.ncbi.nlm.nih.gov/pubmed/15574759?dopt=Citation

Vancouver

Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. CANCER RES. 2004;64(23):8534-8540. 23.

Bibtex

@article{9dae3cea7a8a43cc9756e8f6ad5d5827,
title = "Prognostic relevance of gene amplifications and coamplifications in breast cancer.",
abstract = "Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2. Gene amplification results in oncogene overexpression but may also serve as an indicator of genomic instability. As such, presence of one or several gene amplifications may have prognostic significance. To assess the prognostic importance of amplifications and coamplifications of HER2, EGFR, MYC, CCND1, and MDM2 in breast cancer, we analyzed a breast cancer tissue microarray containing samples from 2197 cancers with follow-up information. Fluorescence in situ hybridizations revealed amplifications of CCND1 in 20.1%, HER2 in 17.3%, MDM2 in 5.7%, MYC in 5.3%, and EGFR in 0.8% of the tumors. All gene amplifications were significantly associated with high grade. HER2 (P <0.001) and MYC amplification (P <0.001) were also linked to shortened survival. In case of HER2, this was independent of grade, pT, and pN categories. MYC amplification was almost 3 times more frequent in medullary cancer (15.9%), than in the histologic subtype with the second highest frequency (ductal; 5.6%; P = 0.0046). HER2 and MYC amplification were associated with estrogen receptor/progesterone receptor negativity (P <0.001) whereas CCND1 amplification was linked to estrogen receptor/progesterone receptor positivity (P <0.001). Coamplifications were more prevalent than expected based on the individual frequencies. Coamplifications of one or several other oncogenes occurred in 29.6% of CCND1, 43% of HER2, 55.7% of MDM2, 65% of MYC, and 72.8% of EGFR-amplified cancers. HER2/MYC-coamplified cancers had a worse prognosis than tumors with only one of these amplifications. Furthermore, a gradual decrease of survival was observed with increasing number of amplifications. In conclusion, these data support a major prognostic impact of genomic instability as determined by a broad gene amplification survey in breast cancer.",
author = "Khawla Al-Kuraya and Peter Schraml and Joachim Torhorst and Coya Tapia and Boriana Zaharieva and Hedvika Novotny and Hanspeter Spichtin and Robert Maurer and Martina Mirlacher and Ossi K{\"o}chli and Markus Zuber and Holger Dieterich and Friedrich Mross and Kim Wilber and Ronald Simon and Guido Sauter",
year = "2004",
language = "Deutsch",
volume = "64",
pages = "8534--8540",
journal = "CANCER RES",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

RIS

TY - JOUR

T1 - Prognostic relevance of gene amplifications and coamplifications in breast cancer.

AU - Al-Kuraya, Khawla

AU - Schraml, Peter

AU - Torhorst, Joachim

AU - Tapia, Coya

AU - Zaharieva, Boriana

AU - Novotny, Hedvika

AU - Spichtin, Hanspeter

AU - Maurer, Robert

AU - Mirlacher, Martina

AU - Köchli, Ossi

AU - Zuber, Markus

AU - Dieterich, Holger

AU - Mross, Friedrich

AU - Wilber, Kim

AU - Simon, Ronald

AU - Sauter, Guido

PY - 2004

Y1 - 2004

N2 - Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2. Gene amplification results in oncogene overexpression but may also serve as an indicator of genomic instability. As such, presence of one or several gene amplifications may have prognostic significance. To assess the prognostic importance of amplifications and coamplifications of HER2, EGFR, MYC, CCND1, and MDM2 in breast cancer, we analyzed a breast cancer tissue microarray containing samples from 2197 cancers with follow-up information. Fluorescence in situ hybridizations revealed amplifications of CCND1 in 20.1%, HER2 in 17.3%, MDM2 in 5.7%, MYC in 5.3%, and EGFR in 0.8% of the tumors. All gene amplifications were significantly associated with high grade. HER2 (P <0.001) and MYC amplification (P <0.001) were also linked to shortened survival. In case of HER2, this was independent of grade, pT, and pN categories. MYC amplification was almost 3 times more frequent in medullary cancer (15.9%), than in the histologic subtype with the second highest frequency (ductal; 5.6%; P = 0.0046). HER2 and MYC amplification were associated with estrogen receptor/progesterone receptor negativity (P <0.001) whereas CCND1 amplification was linked to estrogen receptor/progesterone receptor positivity (P <0.001). Coamplifications were more prevalent than expected based on the individual frequencies. Coamplifications of one or several other oncogenes occurred in 29.6% of CCND1, 43% of HER2, 55.7% of MDM2, 65% of MYC, and 72.8% of EGFR-amplified cancers. HER2/MYC-coamplified cancers had a worse prognosis than tumors with only one of these amplifications. Furthermore, a gradual decrease of survival was observed with increasing number of amplifications. In conclusion, these data support a major prognostic impact of genomic instability as determined by a broad gene amplification survey in breast cancer.

AB - Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2. Gene amplification results in oncogene overexpression but may also serve as an indicator of genomic instability. As such, presence of one or several gene amplifications may have prognostic significance. To assess the prognostic importance of amplifications and coamplifications of HER2, EGFR, MYC, CCND1, and MDM2 in breast cancer, we analyzed a breast cancer tissue microarray containing samples from 2197 cancers with follow-up information. Fluorescence in situ hybridizations revealed amplifications of CCND1 in 20.1%, HER2 in 17.3%, MDM2 in 5.7%, MYC in 5.3%, and EGFR in 0.8% of the tumors. All gene amplifications were significantly associated with high grade. HER2 (P <0.001) and MYC amplification (P <0.001) were also linked to shortened survival. In case of HER2, this was independent of grade, pT, and pN categories. MYC amplification was almost 3 times more frequent in medullary cancer (15.9%), than in the histologic subtype with the second highest frequency (ductal; 5.6%; P = 0.0046). HER2 and MYC amplification were associated with estrogen receptor/progesterone receptor negativity (P <0.001) whereas CCND1 amplification was linked to estrogen receptor/progesterone receptor positivity (P <0.001). Coamplifications were more prevalent than expected based on the individual frequencies. Coamplifications of one or several other oncogenes occurred in 29.6% of CCND1, 43% of HER2, 55.7% of MDM2, 65% of MYC, and 72.8% of EGFR-amplified cancers. HER2/MYC-coamplified cancers had a worse prognosis than tumors with only one of these amplifications. Furthermore, a gradual decrease of survival was observed with increasing number of amplifications. In conclusion, these data support a major prognostic impact of genomic instability as determined by a broad gene amplification survey in breast cancer.

M3 - SCORING: Zeitschriftenaufsatz

VL - 64

SP - 8534

EP - 8540

JO - CANCER RES

JF - CANCER RES

SN - 0008-5472

IS - 23

M1 - 23

ER -